Skip to main content
SpringerLink
Log in

Schwerpunkt CAR-T-Zell-Therapien

Hämatotoxizität und infektiologische Komplikationen unter CAR-T-Zell-Therapie

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

Literatur

  1. Spear P et al. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF. J Immunol. 2012;188(12):6389-98

  2. Shimabukuro-Vornhagen A et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56

  3. Hines MR et al. Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS). Transplant Cell Ther. 2023;S2666-6367(23)01164-8

  4. Karschnia P et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133(20):2212-21

  5. Bachy E et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med.2022;28(10):2145-5

  6. Rejeski K et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021;138(24):2499-513

  7. Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020;136(8):925-35

  8. Melenhorst JJ et al. Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature. 2022;602(7897):503-9

  9. Jain T et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4(15):3776-87

  10. Rejeski K et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J Immunother Cancer. 2022;10(5):e004475

  11. Rejeski K et al. Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report. BMC Infect Dis. 2021;21(1):121

  12. Rejeski K et al. An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA. Hemasphere. 2023;7(5):e889

  13. Juluri KR et al. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. Blood Adv. 2022;6(7):2055-68

  14. Lievin R et al. Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma. Bone Marrow Transplant. 2022;57(3):431-9

  15. Miller KC et al. Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. Blood Cancer J. 2022;12(10):146

  16. Rejeski K et al. Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy. Blood Adv. 2022;6(16):4719-25

  17. Drillet G et al. Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists. Blood Adv. 2023;7(4):537-40

  18. Subklewe M, Benjamin R. Management of Myelotoxicity (Aplasia) and Infectious Complications. In: Kröger N et al., Herausgeber. The EBMT/EHA CAR-T Cell Handbook. Cham (Schweiz): Springer; 2022:151-5

  19. Rejeski K et al. Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL. Hemasphere. 2023;7(4):e858

  20. Hill JA et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood. 2018;131(1):121-30

  21. Haidar G et al. Invasive Mold Infections After Chimeric Antigen Receptor-Modified T-cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis. Clin Infect Dis. 2020;71(3):672-6

  22. Nahas et al. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk Lymphoma. 2020;61(4):940-3

  23. Strati et al. Cytokines associated with prolonged Cytopenia after axicabtagene ciloleucel in patients with refractory large B-cell lymphoma. Cancer Res. 2020;80(16_Supplement):2049

  24. Fried et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplantation. 2019;54(10):1643-50

  25. Wang et al. New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. Front. Oncol. 2021;11:702644

  26. Cordeiro et al. Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. Biol Blood Marrow Transplant. 2020;26(1):26-33

  27. Penack O et al. Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party. J Immunother Cancer. 2023;11(4):e006406

  28. Rejeski K et al. Immune Effector Cell Associated Hematotoxicity (ICAHT) Following CAR T-Cell Therapy: International Survey and Consensus Guidelines on its Grading, Diagnosis, and Management on Behalf of EHA and EBMT. EHA. 2023;Abstr S260

  29. Rejeski K et al. Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA/EBMT Consensus Grading and Best Practice Recommendations. Blood. 2023; https://doi.org/kgtp4

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Marchioninistraße 15, 81377, München, Deutschland

    Kai Rejeski

Authors
  1. Kai Rejeski
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rejeski, K. Hämatotoxizität und infektiologische Komplikationen unter CAR-T-Zell-Therapie. InFo Hämatol Onkol 26, 21–25 (2023). https://doi.org/10.1007/s15004-023-9997-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-023-9997-7

Search

Navigation